Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.84 |
| ▸ | CHAT | P28329 | 2/20 | 0.80 |
| ▸ | EP300 | Q09472 | 4/20 | 0.79 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.79 |
| ▸ | AURKA | O14965 | 2/20 | 0.79 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.79 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 3-Hydroxy-3-Methylglutaryl-Coenzyme A SCHEMBL29353902 | 1.00 | NAA50 (0.84) | NAA50CHATEP300KAT5AURKA | |
| 3-Hydroxy-3-Methylglutaryl-Coenzyme A SCHEMBL20505754 | 1.00 | NAA50 (0.84) | NAA50CHATEP300KAT5AURKA | |
| 3-Hydroxy-3-Methylglutaryl-Coenzyme A SCHEMBL12303241 | 1.00 | NAA50 (0.84) | NAA50CHATEP300KAT5AURKA | |
| 3-Hydroxy-3-Methylglutaryl-Coenzyme A SCHEMBL29371268 | 1.00 | NAA50 (0.84) | NAA50CHATEP300KAT5AURKA | |
| 3-Hydroxy-3-Methylglutaryl-Coenzyme A SCHEMBL4358590 | 1.00 | NAA50 (0.84) | NAA50CHATEP300KAT5AURKA | |
| 3-Hydroxy-3-Methylglutaryl-Coenzyme A SCHEMBL1198 | 1.00 | NAA50 (0.84) | NAA50CHATEP300KAT5AURKA | |
| 3-Hydroxy-3-Methylglutaryl-Coenzyme A SCHEMBL219453 | 1.00 | NAA50 (0.84) | NAA50CHATEP300KAT5AURKA | |
| 3-Hydroxy-3-Methylglutaryl-Coenzyme A SCHEMBL21067504 | 1.00 | NAA50 (0.84) | NAA50CHATEP300KAT5AURKA | |
| 3-Hydroxy-3-Methylglutaryl-Coenzyme A SCHEMBL6382909 | 0.98 | NAA50 (0.88) | NAA50CHATEP300KAT5AURKA | |
| 3-Hydroxy-3-Methylglutaryl-Coenzyme A SCHEMBL5497515 | 0.98 | NAA50 (0.88) | NAA50CHATEP300KAT5AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744817-B2 | High-dose statins for age-related macular degeneration | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2023-09-05 | — | — | US | disclosed |
| US-20210395763-A1 | IMPROVED PRODUCTION OF TERPENOIDS USING ENZYMES ANCHORED TO LIPID DROPLET SURFACE PROTEINS | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2021-12-23 | — | — | US | disclosed |
| US-20210077457-A1 | HIGH-DOSE STATINS FOR AGE-RELATED MACULAR DEGENERATION | MASSACHUSETTS EYE AND EAR INFIRMARY | 2021-03-18 | — | — | US | disclosed |
| US-20200243170-A1 | FUNCTIONAL BIOMARKERS FOR STATIN THERAPY IN AGE-RELATED MACULAR DEGENERATION (AMD) | APELIOTUS TECHNOLOGIES, INC. | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395763-A1 | IMPROVED PRODUCTION OF TERPENOIDS USING ENZYMES ANCHORED TO LIPID DROPLET SURFACE PROTEINS | FADS2, SCD, FADS1 | NAA50 568/4885CHAT 4091/4885EP300 1339/4885 |
| US-20200243170-A1 | FUNCTIONAL BIOMARKERS FOR STATIN THERAPY IN AGE-RELATED MACULAR DEGENERATION (AMD) | LDLR, RBP4, RBP1 | NAA50 4017/4885CHAT 2351/4885EP300 4069/4885 |
| US-11744817-B2 | High-dose statins for age-related macular degeneration | HMGCR, LDLR, STARD3 | NAA50 4339/4885CHAT 2286/4885EP300 2177/4885 |
| US-20210077457-A1 | HIGH-DOSE STATINS FOR AGE-RELATED MACULAR DEGENERATION | HMGCR, LDLR, STARD3 | NAA50 4339/4885CHAT 2286/4885EP300 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.